<li id="omoqo"></li>
  • <noscript id="omoqo"><kbd id="omoqo"></kbd></noscript>
  • <td id="omoqo"></td>
  • <option id="omoqo"><noscript id="omoqo"></noscript></option>
  • <noscript id="omoqo"><source id="omoqo"></source></noscript>
  • 發布時間:2019-04-26 14:24 原文鏈接: PurificationofLin,ckit+,Sca1+bonemarrowcellsforCulture

    MATERIALS

    • Media:

    • Heat inactivated FBS (56°C x 30 min)

    • PBS + 2% heat-inactivated FBS

    • IMDM + 20% heat-inactivated FBS

    • Viral transduction: Iscove's + 20% heat inactivated FBS,

    • plus 100 ng/mL each of SCF, IL-6, and Flt-3L, plus 10 ng/mL IL-11.

    • CFU assays: aMEM +30% FBS, 1% deionized BSA, 1.2% methylcellulose, 0.1mM ?ME.

    • plus 3 U/mL Epo, 50 ng/mL Tpo, 100 ng/mL SCF, 100 ng/mL IL-6, ? ng/mL IL-3.


    • Antibodies for Lineage Depletion: (Pharmingen)

       T-cell: CD2 IgG2b, 01171D B-cell: B220 (CD45R) IgG2a, 01121A
       CD3 IgG2b, 28001D Monocytic: Mac1 (CD11b) IgG2b, 01711A
      •  CD5 IgG2a, 01031D

       Granulocytic: Gr-1 (Ly-6G) IgG2b, 01211A
       D8 IgG2b, 09821D Eryth: Ter-119 IgG2b, 09081A

    • Antibodies for Sorting: (Pharmingen monoclonal rat anti-mouse)

    •  Sca-1 PE-IgG2a (E31-161.7) 01835B PE-IgG2a Isotype control, 11025A
       c-Kit (2B8) FITC-IgG2b, 01904D FITC-IgG2b Isotype control, 11184C
       Fc RII block (clone 2.4G2), 01241D

    • Mice: 

    • C57 (Ly 5.2) 

    • C57/SJL (Ly 5.1, Pep3b)

    •    

    • Other Reagents:

    • Dynabeads (Sheep anti-rat, Dynal #110.08)

    • Ficoll

    • CH296

    • Methylcellulose (Fisher)

    • Deionized BSA (Sigma)

    • Protomine Sulfate


    • Cytokines: (Peprotech)

    • mu SCF

    • hu IL-6

    • hu Flt-3L

    • hu IL-11

    • Thrombopoeitin

    • hu IL-3

    • Erythropoeitin (Amgen)

    PROCEDURE

    Harvest Marrow:
    1. Flush femurs with PBS/FBS and pass cells through a 23G needle.
    2. Also collect T-cells as a flow cytometry control.
    3. Collect low density cells by equilibrium centrifugation over Ficoll-Hypaque (d=1.077 g/mL).
        Alternatively, RBC may be lysed.  See blood flow cytometry protocol for details.
    4. Wash cells in PBS/FBS.

    Lineage Depletion: 
    1. Resuspend at a density of 5x107 cells/mL in PBS/FBS plus antibody cocktail (each antibody final dilution = 1/500 v/v).
    2. Incubate on ice for 30 min. Meanwhile, wash Dynabeads 2x in PBS/FBS.  Resuspend the beads at their original concentration (4 x 108 beads/mL).
    3. Wash cells in PBS/FBS, spin, and resuspend at 108 cells/mL. 
    4. Slowly add 1 vol. of Dynabeads (4 beads/cell) to the cell suspension. Incubate 5 min. @ room temp. 
    5. Expose to magnetic field in a 3 mL round bottom tube or eppendorf tube with the correct sized magnet. Transfer non-adherent cells to a new tube. 
    6. Remove tube with beads from magnet.  Add 1/2 vol. PBS/FBS, gently mix.  Expose to magnet again and pool non-adherent cells with the first.
    7. Optional:  Repeat the lineage depletion with a new round of antibody and beads (steps 1 - 5).
    8. After the last mangetic bead depletion expose the cells to the magnet a second time to remove any remaining beads.  Again, save only the non-adherent cells. 

    Cell Sorting (Lin-,cKit+,Sca1+): 
    1. Incubate cells in FcgRII block on ice for 10 min. 
    2. Stain an aliquot and with PE-IgG2a and FITC-IgG2b isotype antibodies as neg. controls. Incubate remainder of cells with Sca-1 PE, plus c-kit FITC antibodies on ice for 30 min (all antibodies 1/100 v/v).
    4.  Wash with 10 mL of PBS/FBS, spin and resuspend in PBS/FBS with 1 μg/mL of propidium iodide. Filter through 70 μm nylon mesh. 
    5. Select cells which are PI negative, c-kit positive, Sca-1 positive with intermediate forward and side-scatter. (Run T-cells as a size control).

    Viral Transduction: 
    1. Pre-coat 12 well plates with CH-296. To each well add 1.5 mL of Iscove's/20% FBS plus growth factors (SCF, IL-6, Flt-3L, IL-11). 
    2. Collect 5000 cells per well into 12 well plates with 1.5 mL/well of Iscove's transduction media. 
    3. Incubate 48 hrs at 37°C, 5% CO2. 
    4. Harvest cells by spinning at 1000 rpm for 5 min. 
    5. Add 0.5 mL of 3x growth factors to each well (depending on the experiment). 
    6. Resuspend cells in 1 mL of viral supernatant (or control media) and return to wells. 
    7. Incubate 12 hrs at 37°C. 
    8. Repeat viral transduction (steps 4 to 7). Incubate another 12 hrs at 37°C. 
    9. Harvest cells and replate in 1.5 mL of Iscove's/FBS plus growth factors (no virus). 
    10. Incubate 4 days at 37°C.

    Transplant:
    1. Harvest fresh competing marrow from a C57/SJL (Ly 5.1) mouse. Pass through 23G needle and resuspend in Iscove's/FBS at 106 cells mL. 
    2. Harvest cells, wash with Iscove's/FBS. 
    3. Spin at 1400 rpm for 5 min. and resuspend in 1.5 mL. Record cell count. Add 1.1 mL of cells to 1.1 mL of competing marrow cells. Transplant into lethally irradiated (10 Gy, 60Co) recipients. 
    4. Of remaining cells save some for FACS analysis for GFP + lineage specific antibodies; the remainder can be used for CFU assays in methylcellulose. 

    CFU assays:

    1. For CFU assays: Plate an average 20 cells in 35 mm dishes with 1 mL aMEM and 1.2% methylcellulose plus growth factors. 2. Incubate at 37°C in 5%CO2 (plus 5% O2 if available).
    3. Analyze for erythroid colonies at 8 days (and confirm by Benzidine staining). 
    4. At 12 days analyze for granulocyte/macrophage colonies and large (>1.5mm) mixed colonies (erythroid, meg, and granulocytes confirmed by Giemsa staining). 

    GFP and cell surface marker immunostaining: 
    1. Incubate cells with lineage specific antibodies as described for cell sorting, above. If live cells are not needed fixation with dilute formalin or paraformaldehyde is O.K. but alcohol based fixatives should be avoided because they allow GFP to leak out of cells. 
    2. For unconjugated antibodies, incubate with an anti-IgG2 PE-conjugated secondary antibody. 
    3. Wash and incubate with P.I. as for sorting. Analyze on fluorescent microscope or FACS machine.




    相關文章

    科學家將人工智能技術成功用于蛋白質復合物結構預測

    蛋白質作為構成人體組織器官的支架和主要物質,在人體生命活動中起著重要作用。蛋白質的相互作用能產生許多效應,如形成特異底物作用通道、生成新的結合位點、失活、作用底物專一性和動力學變化等,細胞的代謝、信號......

    發力癌癥分子病理診斷,無錫臻和全資收購TissueofOrigin?

    2021年9月9日,無錫臻和生物科技有限公司(以下簡稱“臻和科技”)與美國VyantBio公司簽署TissueofOrigin?(以下簡稱“TOO?”)全球權益和ZL轉讓協議,全資收購這款唯一獲FDA......

    這3個雜志撤回中國學者249篇文章,包含上交、中山等名校

    2021年7月20日,JournalofCellularPhysiology及JournalofCellularBiochemistry同時撤回了中國學者49篇文章。從2019年開始,Journalo......

    研究發現肝臟腫瘤逃脫自然殺傷細胞免疫監視新機制

    自然殺傷細胞(Naturalkillercells,NKcells)是一種效應性淋巴細胞,在人體抗腫瘤過程中發揮重要作用,但是,仍然有一些腫瘤細胞能夠逃避機體NK細胞的攻擊,逐步發生發展,侵襲轉移,嚴......

    腫瘤治療的強心劑,中國學者開發腫瘤治療新策略

    磷酸甘油酸突變酶1(PGAM1)通過其代謝活性以及與其他蛋白質(例如α平滑肌肌動蛋白(ACTA2))的相互作用,在癌癥代謝和腫瘤進展中起關鍵作用。變構調節被認為是發現針對PGAM1的高選擇性和有效抑制......

    StemCellsDev:發現骨形成的新型調節因子

    研究人員發現了小鼠體內一種新的轉錄因子可以幫助調節間充質干細胞(mesenchymalstemcells,MSCs)分化為骨的過程。目前科學家們對于骨細胞分化的研究并不深入,而MSCs則是再生醫學領域......

    島津推出NexeraPrepPurificationLC可節省空間并多樣品處理

    分析測試百科網訊近日,島津公司推出了NexeraPrep系列制備型純化液相色譜儀(LC)。“制備工作”是從樣品中分離和純化特定物質的過程。該過程對于在制藥工業中的藥物發現期間提取目標化合物和雜質以及提......

    llumina宣布推出新型基因分型芯片|支持AllofUs研究計劃

    2018年12月6日,來自圣迭戈的消息——Illumina公司(納斯達克股票代碼:ILMN)今天宣布推出新型高密度基因分型芯片Infinium?GlobalDiversityArray。這款芯片設計源......

    SDSPAGE異常電泳現象及分析SDSPAGEHallofShame

    SDS-PAGE異常電泳現象及分析SDS-PAGEHallofShame.pdf  很不錯的東東~~推薦下~......

    Preparationofdenaturing6%

    Preparationofdenaturing6%polyacrylamidegelsformicrosatelliteanalysis(alsoforSSAP,high-resolutionIRAP......

    <li id="omoqo"></li>
  • <noscript id="omoqo"><kbd id="omoqo"></kbd></noscript>
  • <td id="omoqo"></td>
  • <option id="omoqo"><noscript id="omoqo"></noscript></option>
  • <noscript id="omoqo"><source id="omoqo"></source></noscript>
  • 1v3多肉多车高校生活的玩视频